**Revolution Medicines, Inc. Announces Progress on Daraxonrasib for Pancreatic Cancer**
*October 27, 2025 – 8:53 AM ET*
Revolution Medicines, Inc. is advancing its lead drug candidate, daraxonrasib, targeting pancreatic cancer. The drug is currently being evaluated in the Phase 3 RASolute 302 trial, which focuses on second-line treatment for metastatic pancreatic ductal adenocarcinoma.
**About the RASolute 302 Trial**
The Phase 3 trial aims to assess the efficacy and safety of daraxonrasib in patients who have progressed after first-line therapy. Pancreatic ductal adenocarcinoma is an aggressive form of cancer with limited treatment options, and daraxonrasib offers a novel approach by targeting RAS mutations involved in tumor growth.
**Stock Information: Revolution Medicines, Inc. (Symbol: RVMD)**
– Previous Close: [Insert value]
– Short Interest: [Insert value]
– Last Price: [Insert value]
– Percentage Change: [Insert value]
**Trending Analysis and News**
Revolution Medicines, Inc. (RVMD) has been gaining attention from investors and analysts due to its promising oncology pipeline, with daraxonrasib being a standout candidate. Ongoing updates and news related to the company and its clinical trials are closely watched by market participants.
*Stay tuned for more updates on Revolution Medicines and its progress in developing treatments for pancreatic cancer.*
https://seekingalpha.com/news/4508577-revolution-medicines-nabs-orphan-drug-status-daraxonrasib-pancreatic-cancer?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news